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Background.R e c e n td a t ad e m o n s t r a t e dt h a tt h e−174 G > C IL-6 polymorphism may account for diﬀerences in the therapeutic
response to laparoscopic adjustable gastric banding (LAGB) surgery. Objective. We investigated the impact of −174 G > CI L -
6 polymorphism on weight loss, body composition, and ﬂuid distribution changes in obese subjects after LAGB. Design and
Outcome Measures. Twenty obese subjects were selected and studied at baseline and 3 months after LAGB. Genetic assessment of
−174 G > C IL-6 polymorphism and anthropometric and bioelectrical impedance analysis were performed. Results. At baseline,
C(+) carriers had a lower extracellular water (ECW) and higher intra-CW, phase angle (PA), reactance Xc,a n dXc/height. LAGB
surgery determined signiﬁcant reductions in weight and BMI. After LAGB, in C(−) carriers, signiﬁcant decreases in weight, BMI,
and ECW and increases in BCM, BCMI, ICW, PA, and Xc/H were highlighted. In C(+) carriers, signiﬁcant reductions in weight,
BMI, ICW, and PA and increases in ECW, Na/K, resistance (R), and R/height were obtained. Signiﬁcant higher reductions in
BMI and Xc/H were observed in C(+) with respect to C(−) carriers. Conclusions. Genotyping of genetic variants, for example, the
−174 G > CpolymorphismofIL-6,givestheopportunitytopredicttherapeuticresponse,intermsofbodycompositionoutcomes
after LAGB.
1.Introduction
Assessment of body composition plays an important role
in clinical evaluation and in monitoring absolute and
relative changes during speciﬁc therapeutic regimens in
obese subjects [1]. The weight losses induced by dietary
or surgical treatment are more rapid in the ﬁrst months
and are associated with changes in body composition and
ﬂuid distribution [2]. Along with the increased acceptance
of surgical procedures for weight loss in obesity, clinically
useful baseline and follow-up measures of body composition
and ﬂuid distribution are critical to evaluate interventional
outcomes.
Bioelectrical impedance analysis (BIA) is an easy-to-
use, rapid, and noninvasive method to assess nutritional
status and body ﬂuid composition [3]. Whole-body BIA
allows the determination of the ﬂuid distribution when
usingappropriatepopulation,age-orpathology-speciﬁcBIA
equations, and established procedures [4, 5]. It makes use of
formulas that estimate Total body water (TBW) on the basis2 Journal of Obesity
of the concept that the human body may be approximated to
a cylinder of length equal to body height [6].
Previous data demonstrated that genetic factors which
play an important role in the regulation of body weight may
account for diﬀerences in the therapeutic response to LAGB
[7]. The −174 G > C IL-6 polymorphism, which aﬀects tran-
scriptional regulation [8], may be sensed by the homeostatic
feedback system that controls energy balance and may in
turn contribute to some disturbances in weight regulation,
particularly in a situation of negative energy balance, like
induced weight loss [9]. We recently provided evidence
that the promoter polymorphism of IL-6 (−174 G > C)
gene is associated both with body composition and ﬂuid
distribution, in obese subjects, at baseline and at 6-month
follow-upafterLAGB,suggestingthatLAGBwaslesseﬀective
if the subjects were carrying risk genotypes (C-carriers) for
obesity [10].
The present study aims to investigate the impact of −174
G > C IL-6 polymorphism on nutritional and hydration
status in obese subjects, evaluated by anthropometry and
bioelectrical impedance analysis (BIA), at 3-month follow-
up after LAGB surgery.
2. Methods
2.1. Patients’ Recruitment. The study group consisted of
40 Italian Caucasias with obesity, that is, grade II-III
obesity according to the World Health Organization criteria
[11], consecutively recruited at the San Camillo-Forlanini
Hospital (Rome, Italy) from November 2008 to Novem-
ber 2009. Patients desiring surgical intervention for the
treatment of obesity were referred to the San Camillo-
Forlanini Hospital experienced in the care of obese and
bariatric patients to determine the patients’ eligibility for
surgery on the basis of the international guidelines [12].
Only patients with BMI > 40Kg/m2 or with BMI > 35Kg/m2
with comorbidities, in whom all appropriate nonsurgical
measures failed to achieve or maintain adequate weight
loss for at least 6 months, without any psychiatric prob-
lem and/or drug or alcohol addiction were admitted to
surgery. Exclusion criteria were secondary causes of obesity,
pregnancy, antipsychotic medication, eating disorder, severe
altered self-body image, and nonrealistic expectations about
weight reduction. Psychiatric problems were evaluated on
the basis of tests such as eating disorder examination, body
dysmorphic disorder examination, and other tests related
to general psychopathology [13]. The binge eating scale
(BES), an easily administered 16-item questionnaire with a
range between 0 and 42, was used to assess symptoms of
binge eating. Higher scores indicate greater degree of binge
eating severity [14]. Participation in the study included a
complete medical history to gather information about health
status, current medications history, including supplements
of vitamins and minerals, social habits, like alcohol drinking
and smoking, appetite, physical activity, and family history
for chronic diseases.
Patients were instructed to not modify physical activ-
ity during 3 months of follow-up after LAGB. None of
the patients was receiving drug treatments at the time
of the assessment. If a subject was eligible, an operation
was sched-uled after an informed consent was obtained.
A total of 30 subjects were eligible and admitted to the
intervention and underwent LAGB surgery, an adjustable
gastric band (Lap-Band, Inamed, Santa Barbara, CA, USA).
A multidisciplinary team (an internist, a cardiologist, an
endocrinologist, a gastroenterologist, a psychiatrist, a sur-
geon, a nutritionist) met each patient and provided an
educational session regarding risk and beneﬁts of bariatric
surgery and a nutrition and meal-planning guidance. They
gave consensus for the study assessments, completed the
screening for anthropometry, body composition, and ﬂuid
distribution 3 months after surgery and were successfully
genotyped for the −174 G > CI L - 6p o l y m o r p h i s m .T w e n t y
patients (10 females and 10 males) were selected for data
analysis, to obtain homogeneous groups according to gender
and IL-6 genotypes.
All patient assessments were conducted in collaboration
between San Camillo-Forlanini Hospital and the University
of Rome Tor Vergata, Human Nutrition Unit. The collection
of DNA as well as the experiments was approved by the
Ethical Commission of the University of “Tor Vergata,”
Rome, Italy. A statement of informed consent was signed
by all participants in accordance with principles of the
Declaration of Helsinki.
2.2. Dietary Intervention following LAGB. A standardized
protocol for meal progression after LAGB was assigned to
patients. The acute postoperative diet (ﬁrst and second day)
consisted of noncarbonated clear liquids with no calories,
no sugar, and no caﬀeine. For the ﬁrst month after LAGB, a
semiliquid diet of 850kcal/d was prescribed (33% proteins,
19% lipids, 48% carbohydrates). One month after LAGB,
a solid diet was reintroduced, and the suggested diet was
1200kcal/d; iron was supplemented on the basis of blood
examinations performed during the second month. Diet
included 48% carbohydrates (starch or bread), 33% proteins
(fat-free parts of diﬀerent animals and ﬁsh), and 19% lipids
(olive oil); sweets, cakes, sweetened drinks, alcohol, and
animal lipids were forbidden. Compliance of diet (and PA)
was reviewed monthly by the multidisciplinary team.
2.3. Anthropometric Measurements. After a 12-hour over-
nightfast,allsubjectsunderwentanthropometricevaluation.
Anthropometric parameters of all the partici-pants were
measured according to standard methods (body weight
(BW) and height) [15]. Subjects were instructed to take
oﬀ their clothes and shoes before performing all the mea-
surements. BW (kg) was measured to the nearest 0.1kg,
using a balance scale (Invernizzi, Rome, Italy). Height (cm)
was measured using a stadiometry to the nearest 0.1cm
(Invernizzi, Rome, Italy). BMI was calculated using the
formula: BMI = BW (kg)/height (m)2.
2.4. Bioelectrical Impedance Analysis (BIA). Resistance (R),
reactance (Xc), impedance, and phase angle (PA) at 50kHz
frequency (Single Frequency, SF) were measured usingJournal of Obesity 3
Table 1: Description of study population according to genotypes.
Parameters C(−)( n = 10) C(+) (n = 10)
Age1 40.50 ±6.74 43.50 ±13.37
Gender (M/F) 5/5 5/5
Obesity of II degree (%) 10 9.1
Obesity of III degree (%) 90 89.9
IL-6 (pg/mL)1 3.27 ±0.41 2.85 ±0.44
BES1 2.17 ±0.98 2.60 ±0.70
1Values expressed as arithmetic x ± SD. BES, Binge Eating Scale.
Table 2: Anthropometric and BIA parameters at baseline and week
12 after LAGB.1
Parameters Baseline Week 12
Total (n = 20) Total (n = 20)
Weight (Kg) 126.06 ±23.53 114.17 ±23.683
BMI (Kg/m2)4 6 .05 ±8.81 41.32 ±8.413
BCM (Kg) 38.01 ±8.97 37.72 ±10.07
BCM (%) 55.71 ±9.17 56.64 ±4.26
BCMI 13.61 ±3.05 13.58 ±2.52
TBW (L) 50.35 ±10.01 48.62 ±10.622
TBW (%) 40.98 ±7.20 43.90 ±7.503
ECW (L) 21.27 ±3.99 20.66 ±3.84
ECW (%) 42.48 ±4.30 42.90 ±4.07
ICW (L) 29.08 ±6.96 27.97 ±7.28
ICW (%) 57.53 ±4.30 57.08 ±4.04
PA (◦)6 .86 ±1.13 6.73 ±0.98
Na/K 0.77 ±0.08 0.80 ±0.09
R (ohm) 408.65 ±53.42 422.10 ±66.74
R/H (ohm/m) 247.75 ±37.99 256.84 ±50.70
Xc (ohm) 48.90 ±8.56 49.15 ±6.97
Xc/H (ohm/m) 29.57 ±5.40 29.78 ±4.73
1All values are arithmetic x ± S D .B M I ,b o d ym a s si n d e x ;B C M ,b o d yc e l l
mass; TBW, total body water; ECW; extracellular water; ICW; intra-cellular
water; PA, phase angle; R, resistance; H,h e i g h t ;Xc,r e a c t a n c e .
2Reﬂects the signiﬁcance of the diﬀerences between baseline and week 12
determined with a paired t-test (P ≤ 0.05).
3Reﬂects the signiﬁcance of the diﬀerences between baseline and week 12
determined with a paired t-test (P ≤ 0.001).
a BIA phase-sensitive system (BIA 101S, Akern/RJL Systems-
Florence, Italy). Measurements were taken on left side of
the body, with injection and sensor electrodes placed on the
handandfootinreferenceposition.TBW,extracellularwater
(ECW), intra-cellulat water (ICW), Na/K ratio, PA, body cell
mass (BCM), and body cell mass index (BCMI) were calcu-
lated from bioelectrical measurements and anthropometric
data by applying the software provided by the manufacturer,
which incorporated validated predictive equations [16–20].
2.5. DNA Genotyping. Volunteers were genotyped for the
−174 G > C IL-6 gene promoter polymorphism. Genomic
leukocyte DNA was extracted from peripheral blood
according to the standard procedure. The genotyping of
−174 G > C IL-6 polymorphism was performed by poly-
merase chain reaction using primers previously published
[21] and was followed by the single-strand conformation
polymorphism analysis. The CC and the GC genotypes were
grouped and indicated as C carriers (C+), and GG genotype
was named as C noncarriers (C−). Among Europeans
genotype frequencies are 50% of GG, 35% of GC, and 15%
of CC (http://www.SNPedia.com/).
2.6.StatisticalAnalysis. Dataarepresentedasgroupmeans ±
SD or percentage. Data were analyzed to check assumptions
about the distribution of the measured variables. An χ2 test
wasalso used to evaluate the Hardy-Weinberg equilibrium of
theobservedgenotypefrequencieswithrespecttothegeneral
population. Three genotype groups were ﬁrst considered to
check diﬀerences in considered variables between groups.
Because a dominant or recessive eﬀect existed, analysis
was repeated comparing carriers (C+) versus noncarriers
(C−) groups. Comparisons among genotype groups were
performed using analysis of variance. A paired t-test was
performed to evaluate diﬀerences before and after LAGB
surgery. All tests were considered signiﬁcant at P ≤ 0.05.
Statistical analysis was performed using a computer software
package (SPSS for Windows, version 13.0; SPSS, Chicago, IL,
USA).
3. Results
Table 1 shows baseline characteristics of all the study pop-
ulation according to −174 G/C IL-6 genotypes. According
to WHO criteria of obesity, based on BMI evaluation, most
of the subjects were obese of II degree at the starting
point, before LAGB intervention. According to BES ques-
tionnaire, no patients showed binge eating disorders. No
association between −174 G > C IL-6 polymorphism and IL-
6 plasma levels at baseline was observed. No postoperative
complications occurred in selected patients. After surgery,
a signiﬁcant reduction in food intake was observed at the
repeated dietary assessments, and the composition of the
diet ﬁts quite well with dietary prescriptions, with a good
nutritional compliance (data not shown).
3.1. Eﬀects of LAGB on Anthropometric and BIA Parameters.
We evaluated the eﬃcacy of LAGB surgery and the eﬀects
on anthropometry and body composition by BIA analysis
of patients after 12 weeks follow-up (Table 2). LAGB surgery
determined signiﬁcant reductions in weight (Δ% =− 9.70 ±
4.39, P<0.001) and BMI (Δ% =− 10.31±5.11, P<0.01). A
signiﬁcant decrease of TBW (L) and an increase of TBW (%)
after intervention were observed.
3.2. Genotyping Assessment. The distribution of the IL-6
genotypes in the total screened population (n = 30) was
compatible with the Hardy-Weinberg equilibrium. The C
allele frequency was 35.0%, and the GG, GC, and CC
genotype frequencies were 45%, 40%, and 15%, respectively.
The study population (n = 20) was subgrouped in 2 groups,4 Journal of Obesity
Table 3: Anthropometric and BIA parameters at baseline and week 12 after LAGB, according to genotypes1.
Parameters Baseline Week 12
C(−)( n = 10) C(+) (n = 10) C(−)( n = 10) C(+) (n = 10)
Weight (Kg) 135.65 ±20.17 117.34 ±23.79 124.95 ±21.114 104.36 ±22.334,2bis
BMI (Kg/m2)4 8 .86 ±9.29 43.25 ±7.74 44.97 ±9.204 37.67 ±5.914,2bis
BCM (Kg) 37.68 ±8.29 38.27 ±9.89 40.31 ±8.652 35.60 ±11.03
BCM (%) 52.14 ±5.93 58.63 ±10.54 56.67 ±3.293 56.61 ±5.09
BCMI 13.32 ±2.50 13.85 ±3.54 14.33 ±2.183 12.96 ±2.71
TBW (L) 52.63 ±8.26 48.47 ±11.28 51.73 ±9.19 46.07 ±11.44
TBW (%) 40.17 ±8.20 41.64 ±6.60 43.30 ±9.203 44.38 ±6.222
ECW (L) 23.32 ±3.37 19.50 ±3.682bis 21.84 ±2.893 19.68 ±4.37
ECW (%) 44.69 ±3.51 40.66 ±4.152bis 42.64 ±3.462 43.11 ±4.672
ICW (L) 29.21 ±5.60 28.97 ±8.18 29.89 ±6.63 26.39 ±7.723
ICW (%) 55.31 ±3.51 59.34 ±4.142bis 57.36 ±3.462 56.85 ±4.613
PA (◦)6 .28 ±0.80 7.34 ±1.162bis 6.77 ±0.852 6.69 ±1.113
Na/K 0.79 ±0.10 0.75 ±0.05 0.79 ±0.09 0.81 ±0.082
R (ohm) 396.44 ±54.18 418.64 ±53.20 393.40 ±58.96 444.64 ±64.092,2bis
R/H (ohm/m) 238.59 ±35.58 255.24 ±39.90 235.87 ±41.32 272.33 ±52.902,2bis
Xc (ohm) 43.67 ±8.34 53.18 ±6.233bis 46.90 ±5.86 51.45 ±7.16
Xc/H (ohm/m) 26.18 ±4.58 32.35 ±4.442bis 27.99 ±3.062 31.39 ± 5.292bis
1All values are arithmetic x ± SD. BMI, body mass index; BCM, body cell mass; TBW, total body water; ECW; extracellular water; ICW; intracellular water;
PA, phase angle; R, resistance; H,h e i g h t ;Xc,r e a c t a n c e .
2Reﬂects the signiﬁcance of the diﬀerences between baseline and week 12 determined with a paired t-test (P ≤ 0.05).
3Reﬂects the signiﬁcance of the diﬀerences between baseline and week 12 determined with a paired t-test (P ≤ 0.01).
4Reﬂects the signiﬁcance of the diﬀerences between baseline and week 12 determined with a paired t-test (P ≤ 0.001).
2bisReﬂects the signiﬁcance of the diﬀerences between genotypes at baseline and week 12 determined with an independent t-test (P ≤ 0.05).
3bisReﬂects the signiﬁcance of the diﬀerences between genotypes at baseline and week 12 determined with an independent t-test (P ≤ 0.05).
that is, (C+) and (C−) carriers of the −174 G/C IL-6 gene
polymorphism, as deﬁned above.
3.3. Eﬀects of LAGB on Anthropometric and BIA Parameters
according to Genotypes. To investigate if genetic proﬁle
aﬀects changes occurring after LAGB surgery, we compared
anthropometric and body composition changes in subgroup
patientsaccordingtogenotypes.Table 3 showstheanalysisof
varianceofallvariablesassessedinC(−)versusC(+)carriers,
at baseline and at week 12. At baseline, C(+) carriers had a
lower ECW (L, %) and higher ICW (%), PA, Xc,a n dXc/H.
A tw e e k1 2 ,ad i ﬀerence in weight, BMI, R, R/H,a n dXc/H
between C(+) and C(−) carriers was observed.
After LAGB, in C(−) carriers, signiﬁcant decreases in
weight, BMI, and ECW (L, %) and increases in BCM (L, %),
BCMI, TBW (%), ICW (%), PA, and Xc/H were highlighted.
In C(+) carriers, signiﬁcant reductions in weight, BMI, ICW
(L, %), and phase angle and increases in TBW (%), ECW
(%), Na/K, R, and R/H were obtained.
As reported in Figures 1 and 2, we highlighted a strong
variability in relative changes of BMI, Xc/H, and R/H,a f t e r
restrictive bariatric surgery, according to genotypes. Signiﬁ-
cant higher reduction in BMI (Δ% =− 12.63 ± 4.11 versus
Δ% =− 8.00 ± 5.13; P ≤ 0.05), and Xc/H (Δ% =− 2.79 ±
12.51 versus Δ% = 7.62 ± 11.63; P ≤ 0.05), was observed in
C(+) with respect to C(−) carriers.
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Figure 1: Relative changes of BMI 12 weeks after LAGB, according
to genotypes. (Data are expressed as median, SD, and CI. SD,
standard deviation; CI, conﬁdence interval. #P ≤ 0.05 for C(−)
carriers versus C(+) carriers with independent t-sample test).
4. Discussion
Because of several, but not really exhaustive, data regard-
ing the individual response to weight loss interventions,Journal of Obesity 5
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Figure 2: Relative changes of resistance over height (R/H)a n d
reactance over height (Xc/H) 12 weeks after LAGB, according to
genotypes. (Data are expressed as median, SD, and CI. SD, standard
deviation; CI, conﬁdence interval. ∗P ≤ 0.05 for C(−) carriers
versus C(+) carriers with the Mann-Whitney test).
depending on genetic variants, such as the promoter −174
G > C polymorphism of IL-6, the aim of this study was
to explore the relationships between body weight, body
composition and ﬂuid distribution, and the −174 G > CI L - 6
polymorphism in obese subjects, before and 3 months after
LAGB.
According to BMI, at baseline, only the 10% of the
subjects were aﬀected by obesity of II degree. However, for
further investigation we considered the total population tak-
ing in account the body composition rather than BMI. Any
diﬀerences between C(−) and C(+) carriers were observed.
The results show that a signiﬁcant weight reduction in all
the study population, 3 months after LAGB, was observed.
However, not all subjects showed decrease in weight. On
average, individuals who have bariatric surgery lose about
25% of their initial body weight within the ﬁrst 12 months
postoperatively [22, 23]. At 3 months after LAGB, only
the 60% of total subjects lost at least 10% of initial body
weight. More speciﬁcally, there was a higher number of no
responders (less than 10% of body weight loss) between
C(−)andC(+)carriers(60%versus20%).Moreover,despite
the no signiﬁcant changes in body composition and ﬂuid
distribution, evaluated by BIA, in all the study population,
ad i ﬀerence between IL-6 genotypes, both before and after
LAGB, occurred. C(−) carriers, other than losing less weight
with respect to C(+) carriers (Figure 1, i.e., Δ%o fB M I ) ,
incurred in signiﬁcant increases in BCM (Kg, %), BCMI,
TBW (%), ICW (%), PA (◦), and Xc/H (Figure 2, i.e., Δ%
of Xc/H). On the other hand, C(+) carriers showed a lower
ECW (%), and higher levels of ICW (%), PA (◦), Xc,a n d
Xc/H, at baseline. Diﬀerently from C(−) carriers, C(+)
carriersreducedICW(%)andPA(◦),withoutaﬀectingBCM
(Kg, %), but increased ECW (%), R and R/H. Therefore,
ICWreductioncouldbeaconsequenceofleancellshrinking,
d u et ow e i g h tl o s s[ 1, 2]. SF-BIA permits to estimate TBW,
but cannot determine diﬀerences in ICW [4]. In fact, SF-
BIA primarily reﬂects the ECW space, which represents a
constant proportion of TBW in subjects without signiﬁcant
ﬂuid and electrolyte abnormalities. These ﬁndings clearly
demonstrate that the −174 G > Cp o l y m o r p h i s mo fI L - 6
has an impact on the response to weight loss induced by
LAGB, in terms of body composition and ﬂuid distribution
outcomes, at 3 months after intervention.
It is important to note that previous studies have shown
that during the ﬁrst months after LAGB, the patients
experienced the most dramatic weight loss, because they
were very compliant to the administered diet. In this clinical
situation, it is possible to reveal the true impact of given
genetic polymorphisms or their combination on weight loss
after LAGB. Thus, we aimed to explore the impact of −174
G > C IL-6 polymorphism 3 months after LAGB through
anthropometry and BIA analysis.
Several mechanisms may explain the association of the
−174 G > C IL-6 polymorphism and body composition at
baseline and changes after LAGB. IL-6 can regulate energy
expenditure centrally,asit is expressed inhypothalamus,and
adipose tissue homeostasis [24–28].
To the best of our knowledge, the eﬀect of IL-6 (−174
G > C) polymorphism on body composition, ﬂuid distri-
bution after 3 months of LAGB has not been studied yet.
M o r e o v e r ,e v e ni fd a t ao nb o d yc o m p o s i t i o nc h a n g e sa f t e r
weight loss are numerous, only few studies investigated ﬂuid
modiﬁcations [1, 2]. Sesti et al. reported that −174 G > CI L -
6 polymorphism is associated with increased weight loss in
morbidly obese subjects at 6-month follow-up after LAGB
[7]. Poitou et al. in 2005 showed a relationship between
−174 G > C IL-6 polymorphism and circulating product
in morbidly obese subjects, during weight loss after surgery
[9]. In our previous study, at 6-month follow-up after LAGB
surgery, according to IL-6 genotypes, no diﬀerences in ﬂuid
distribution were highlighted [10].
Limitationsofthepresentstudy,whichshouldbeconsid-
ered, include the small sample size. On the other hand, our
sample size of 20 subjects represented a very homogeneous
group, according to gender and genotypes groups. Secondly,
all subjects of the study group underwent the same bariatric
intervention, that is, LAGB, associated to a well-balanced
low-calorie diet.
Although larger study populations are needed to conﬁrm
this observation, this ﬁnding is comparable with our previ-
ous study [10], which has reported the relationship between
the −174 G > C polymorphism of IL-6 and therapeutic
response to bariatric surgery.
In conclusion, we demonstrated that genotyping of
genetic variants, such as the −174 G > Cp o l y m o r p h i s mo f
IL-6, gives the opportunity to predict therapeutic response
of obese subjects, in terms of body composition outcomes,
through bioelectrical evaluation.6 Journal of Obesity
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